Neos Therapeutics

Neos Therapeutics Acquires all Commercialization and Profit Rights to Generic Tussionex® (Extended Release Hydrocodone Polistirex/Chlorpheniramine Polistirex) from Chiesi USA and Coating Place, Inc.

Dallas-Fort Worth, TX, Cary, NC and Verona, WI (September 8, 2014) – CMEA Capital portfolio company Neos Therapeutics, Inc. (“Neos”), a specialty pharmaceutical company with a portfolio of novel and proprietary oral drug delivery technologies as well as a late-stage pipeline of innovative extended release (“XR”) products for Attention Deficit Hyperactivity Disorder (“ADHD”), announced today the completion of the acquisition of all of the commercialization and profit rights to its Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended Release Suspension Product from its collaboration partners Chiesi USA, Inc., and Coating Place, Inc.

The antitussive/antihistamine combination product is a generic equivalent of the product currently sold under the Tussionex® brand name. The product is indicated for the relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children six years of age and older. According to Symphony Health Solutions, a third-party provider of prescription data, there were approximately 2.5 million total prescriptions of Tussionex® and related generic products in 2013.

“We are pleased to acquire the full rights to this product as we believe that there is a significant opportunity to expand our sales given the demand within the market. Antitussives are among the most commonly prescribed medications for the treatment of coughs and colds,” said Dr. Vipin K. Garg, President and CEO of Neos. “Establishing a commercial presence is a natural progression for Neos as its late-stage ADHD pipeline moves forward in the approval process,” he added.

“This transaction is in alignment with our strategy to focus our growth of the company in the hospital and related specialty markets,” said Ken McBean, President of Chiesi USA. “We are pleased that Neos, our manufacturing partner for the product, will now have the opportunity to also market this product.”

“We are committed to continuing our relationship with Neos as its exclusive supplier of the drug resin complexes used in the suspension” added Tim Breunig, CEO of Coating Place, Inc.”

About Neos Therapeutics

Neos Therapeutics, Inc. is a fully integrated specialty pharmaceutical company. The Company is initially focusing on ADHD with three proprietary products in late-stage development that provide patient-friendly dosage forms incorporating controlled and extended release oral disintegrating tablets (ODT) and liquid suspensions. In addition, Neos manufactures and markets a Generic of Tussionex®, for the treatment of cough and cold. The Company’s products are developed and manufactured using its proprietary and patented ion resin technology. For more information, visit www.neostx.com.

About Chiesi USA, Inc.

Chiesi USA, Inc., headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Key elements of the Company’s strategy are to focus its commercial and development efforts in the hospital and adjacent specialty product sector within the U.S. pharmaceutical marketplace; continue to seek opportunities to acquire companies, marketed or registration-stage products and late-stage development products that fit within the Company’s focus areas; and generate revenues by marketing approved generic products through the Company’s wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. For more information, visit www.chiesiusa.com.

About Chiesi Farmaceutici S.p.A.

Chiesi Farmaceutici is a research-focused international group, with more than 75 years of experience headquartered in Parma (Italy). Chiesi researches, develops and commercializes innovative pharmaceutical solutions in the respiratory therapeutics and specialist medicine areas. In 2013, Chiesi achieved sales of over 1.2 billion Euros, constituting double digit growth over 2012. Its R&D centers in Parma (Italy), Paris (France), Rockville (USA), Chippenham (UK) and the R&D team of the newly-acquired Danish company Zymenex, integrate their efforts to advance Chiesi’s pre-clinical, clinical and registration programs. The Chiesi Group employs approximately 3900 people, 480 of whom are dedicated to R&D activities. For more information, please visit www.chiesi.com.

About Coating Place, Inc.

Coating Place is an innovative pharmaceutical company specializing in Wurster fluid bed technology focused on drug delivery system development and contract manufacturing.  We provide our customers with modified & extended release bulk active products through cutting-edge development, unique manufacturing capabilities and integrated quality philosophy.  CPI’s extended release drug-resin API’s are developed using our patented DRC Technology combined with our trade secret linear scale-able Wurster manufacturing process. For more information, please visit www.coatingplace.com.

Tussionex® is a registered trademark of the UCB Group of companies.

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

Foro Energy

Petrobras and Foro Energy Announce Signing of Technology Cooperation Agreement

HOUSTON–(BUSINESS WIRE) – August 26th, 2014 Petrobras and Foro Energy today announced the signing of a Technology Cooperation Agreement (TCA) for high power laser drilling research and development. The program with the Leopoldo Americo Miguez de Mello Research & Development Center (CENPES) will focus on developing a next generation high power laser drilling system. The TCA sets the framework for collaborative research between Petrobras and Foro Energy over an initial three-year time period with the opportunity for extensions.

The ultimate goal of the collaboration will be to achieve a step change in drilling performance in the challenging pre-salt (subsalt) reservoir. High power lasers have the potential to deliver step change performance in drilling by increased rate of penetration, extremely low weight on bit and torque, thereby prolonging bit life and lower drilling cost per foot.

The Technology Cooperation Agreement was signed by Andre Cordeiro Executive Manager of CENPES and Paul Deutch, CEO of Foro Energy. It follows a previously signed Memorandum of Understanding (MoU) between the two companies enabling the opportunity for wider collaboration in utilizing high power lasers for additional applications.

Petroleo Brasileiro S.A. — Petrobras (NYSE:PBRwww.Petrobras.com.

Foro Energy www.ForoEnergy.com. Foro Energy is commercializing high-power lasers for the oil, natural gas, geothermal and mining industries. Their hardware platform transmits high-power lasers over long distance using fiber optic cables to more efficiently drill, complete and work over wells.

Contact:
Foro Energy
Paul Deutch, 713-456-3350

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

Odyssey Logistics

Odyssey Logistics & Technology Corp. (Odyssey) Announces the Acquisition of ADS Logistics

DANBURY, Conn. (August 26, 2014) –Odyssey Logistics & Technology Corporation (Odyssey), a leader in global supply chain logistics, today announced the acquisition of Alternative Distribution Systems Logistics Company, Inc. (ADS Logistics), a full service metals logistics provider based out of Chesterton, Indiana.

Established in 1978, ADS Logistics offers trucking, warehousing, and intermodal services through its three divisions: Area Transportation, Roll & Hold, and Western Intermodal. Area Transportation utilizes both asset-based and independent contractor fleets, servicing primarily the Midwest, Mid-Atlantic, West Coast, and several Southern regions. Roll & Hold has approximately 500,000 square feet of storage space and value added services in five strategically placed locations.

Western Intermodal facilities ship material between Chicago, IL and the West Coast and are capable of providing drayage and trans- loading services as well as temporary storage for on-demand shipment to customers.

The acquisition strengthens Odyssey’s existing leadership position. Bob Shellman, CEO of Odyssey, commented, “ADS Logistics is a tremendous addition to our intermodal network and brings both trucking and warehousing capabilities.”

Bill Ritter, President and CEO of ADS Logistics, added, “Becoming part of the Odyssey family of logistics services is an excellent opportunity for us. Odyssey shares our values of safety, service, and professionalism, and with its large network, leading edge technology, and logistics expertise we will provide our customers with an even broader range of services and solutions.”

About Odyssey

Odyssey Logistics & Technology Corporation (Odyssey) is a global lead logistics solutions provider offering a broad array of services to support the shipment of cargoes, estimated at over $60B, moving both domestically and internationally to over 100 ports around the world. With operations in North America, Europe and the Far East, Odyssey operates in all modes of transport with TL/LTL trucking, containership, rail, air, and the more complex areas of bulk transport including bulk truck, ISO Tank, railcar and tanker, as well as food-grade product lines. Odyssey’s services include truck brokerage, intermodal transportation, customs brokerage, freight forwarding, facilities management, rail fleet management, sample and small order distribution and more.

The Odyssey Global Logistics PlatformSM features a transportation management system that supports the safe, reliable and efficient delivery of client’s products throughout the world. WIN (Web Integrated Network) offers a scalable technology solution with an accelerated deployment and faster time to value.

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

Arcadia Biosciences

ARCADIA BIOSCIENCES RECEIVES U.S. PATENT FOR EXTENDED SHELF LIFE TOMATOES

Technology Helps Vine-Ripened Tomatoes Stay Fresh from Farm to Table

DAVIS, Calif. (July 17, 2014) — Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, today announced that the U.S. Patent and Trademark Office has granted the company a key technology patent for Extended Shelf Life (ESL) tomatoes.

The patent covers the non-transgenic modification of a gene in tomato plants that slows the post-harvest ripening of the tomato.  “Arcadia’s ESL technology allows tomatoes to maintain fresh quality, better flavor and nutrition while retaining the firmness needed during the shipping and marketing process,” said Eric Rey, president and CEO of Arcadia Biosciences. “This technology offers tremendous value for both producers and consumers of tomato food products, including fresh market tomatoes, canned tomatoes, ketchups, soups, sauces, pastes and juices.”

Globally, an estimated 10-35 percent of tomatoes are lost to post-harvest spoilage. Using a non-GM advanced screening and breeding technique called TILLING®, Arcadia has selected tomato lines with altered function of the non-ripening (nor) gene. This results in tomatoes that retain the desirable qualities of vine-ripened fruit, but are resistant to rapid post-harvest softening. Producers benefit from reduced waste and spoilage during production and shipping, providing consumers with fully ripe and fresh tomatoes.

Other alterations to the non-ripening gene in tomatoes are widely available, but they adversely impact tomato flavor because their effects are too severe. Arcadia’s technology uniquely offers intermediate levels of ripening that can be recombined using traditional breeding to produce tomatoes that are superior to existing elite commercial varieties for both producers and consumers.

Arcadia’s ESL technology was developed in part under a U.S. Department of Defense contract to develop longer-lasting fresh produce for field troops stationed in remote locations. Arcadia’s patent portfolio now includes more than 107 technology patents in the U.S., Europe, China, Vietnam, Australia, Mexico, and other key geographies for agricultural production.

About Arcadia Biosciences, Inc.

Based in Davis, Calif., Arcadia Biosciences is an agricultural technology company focused on the development of agricultural products that benefit the environment and enhance human health. Arcadia’s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salt Tolerance, Heat Tolerance, and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition technologies and products create healthier ingredients and whole foods with lower production costs. The company was recently named one of MIT Technology Review’s 50 Smartest Companies and was previously recognized by AlwaysON as one of the GoingGreen Silicon Valley Global 200. For more information visit www.arcadiabio.com.

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

 

Neos Therapeutics

Neos Therapeutics Announces Positive Phase 3 Study Results for its Methylphenidate Extended-Release (XR) Oral Disintegrating Tablet (ODT) in ADHD Patients

Grand Prairie, TX (July 15, 2014) –  CMEA Capital portfolio company Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with a portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has completed a positive Phase 3 study for its methylphenidate XR-ODT drug candidate, NT-0102, in children with ADHD.

The trial was a multicenter, randomized, double-blind, placebo-controlled laboratory classroom study in 87 children with a diagnosis of ADHD. NT-0102 met primary and secondary efficacy endpoints, showing statistically significant improvement on both the Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale (SKAMP) and the Permanent Product Measure of Performance (PERMP) scale, through 12 hours post-dose. No serious adverse events were reported during the study and the adverse event profile was consistent with the drug’s mechanism of action.

“ADHD is a condition that causes significant distress for patients and caregivers. Although, there are a number of effective long-acting medications currently on the market, most formulations consist of tablets or capsules that can be difficult for children to swallow. The positive data from this study is exciting. Hopefully, soon we will have a once-daily oral disintegrating tablet option that is easy to administer to patients,” said Dr. Ann Childress (Center for Psychiatry and Behavioral Medicine, La Vegas, NV), lead investigator for the study.

“We are very pleased to have worked with Dr. Childress on this study. Having a potential treatment option for those who cannot swallow other dosage forms is important, especially in a chronic disorder like ADHD, in which children may struggle to take their medication or develop pill fatigue,” noted Dr. Carolyn Sikes, Vice President of Clinical Development at Neos.

Stimulant medications, such as methylphenidate, have been available for the treatment of ADHD for decades. Extended-release formulations of these medications allow for once-daily dosing, however recent data suggest that a significant percentage of children and adolescents struggle to ingest tablets or capsules. An XR-ODT formulation, which does not require swallowing an intact tablet or capsule and can be dosed once daily, may offer a practical alternative.

Dr. Vipin Garg, President and CEO of Neos, added that “We are delighted with these robust clinical results, as this data validates our XR-ODT technology. We believe that our methylphenidate and amphetamine XR-ODT formulations could provide a patient-friendly dosage form for both children and adults with ADHD. We are looking forward to filing the NDA for our NT-0102 drug candidate in the near future.”

About ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurobehavioral disorder characterized by excessive levels of inattention and/or hyperactivity/impulsivity for an individual’s age and level of development, which causes significant functional and social impairment. The disorder begins in childhood and up to 9.5% of children (ages 4-17) have received a diagnosis of ADHD (about 5.4 million school-aged children). For up to 50% of these individuals, the condition or symptoms of the condition persist into adulthood.

About Neos Therapeutics
Neos Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and manufacture of FDA approved drug products that utilize the Company’s proprietary and patented delivery technologies. The Neos drug products are being developed using the Dynamic Time Release Suspension® (DTRS®) and Rapidly Disintegrating Ionic Masking™ (RDIM™) technologies that deliver controlled release (CR) small molecule active pharmaceutical ingredients (APIs) in either liquid or oral disintegrating tablet (ODT) dosage forms. By utilizing APIs that are already FDA-approved, Neos can reduce development and regulatory risk and efficiently advance targeted proprietary Rx products through the FDA’s New Drug Application (NDA) approval process. For more information, visit www.neostx.com.

Dynamic Time Release Suspension® and DTRS® are registered trademarks of Neos Therapeutics, LP, an affiliate of Neos Therapeutics, Inc., and Rapidly Disintegrating Ionic MaskingTM and RDIMTM are trademarks of Neos Therapeutics, Inc.

This press release contains certain forward-looking statements that include projections and may also include words such as may, will, expects, believes, anticipates, plans, estimates, seeks, could, intends, and other similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

CONTACTS

Vipin K. Garg, Ph.D.

President and CEO

(919) 434-6643

vgarg@neostx.com

Richard Eisenstadt, MBA

Chief Financial Officer

(972) 408-1389

reisenstadt@neostx.com

Baxano

Baxano Surgical Announces First Clinical Use of the Avance MIS Pedicle Screw System

Raleigh, NC – June 30, 2014 (GLOBE NEWSWIRE) —  CMEA Capital portfolio company Baxano Surgical, Inc. (Nasdaq:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, today announced that the first case utilizing the AvanceT MIS Pedicle Screw System was recently performed by Dr. Sameer Mathur in Cary, NC.   The innovative design of Avance provides for an easy-to-use, percutaneous pedicle screw system that addresses single, complex and multi-level spinal pathologies with minimal tissue disruption and trauma.  The Avance system will be in limited market release through the end of third quarter of 2014 and is planned for full launch in the fourth quarter of 2014.

“The first clinical use of the Avance pedicle screw system represents a major milestone in the evolution of Baxano Surgical,” stated Ken Reali, President and CEO of Baxano Surgical.  “Avance will significantly enhance our ability to service our surgeon customers’ lower lumbar fusion needs where we can now offer a complete fusion solution coupled with our AxiaLIF and VEO interbody fusion implants.  This is an important strategic initiative that increases our presence in the rapidly growing MIS spine arena.”

“The Avance system provides a step forward with a true MIS approach to spinal fixation by minimizing tissue trauma and eliminating additional rod insertion incisions,” stated spine surgeon Sameer Mathur, M.D.  “The system’s low-profile design, combined with Avance’s intraoperative flexibility and range of options to meet surgeon preferences makes for a durable, versatile, easy-to-use solution.”

About the Avance MIS Pedicle Screw System The Avance MIS Pedicle Screw System is intended for posterior, non-cervical pedicle fixation of the spine to provide immobilization and stabilization of spinal segments in skeletally-mature patients as an adjunct to fusion for the following indications: degenerative disc disease, spondylolisthesis, trauma, spinal stenosis, curvatures, tumor, pseudoarthrosis and failed previous fusion.  The Avance system accommodates single level degenerative procedures as well as multi-level, complex pathologies from T1 to S1.

About Baxano Surgical, Inc.
Baxano Surgical, Inc. is a medical device company focused on designing, developing, and marketing minimally invasive products to treat degenerative conditions of the spine affecting the lumbar region. Baxano Surgical currently markets the AxiaLIF® family of products for single and two level lower lumbar fusion, the VEO® lateral access and interbody fusion system, the iO-Flex® system, a proprietary set of flexible instruments used by surgeons during spinal decompression procedures, the iO-Tome® instrument, which rapidly and precisely removes bone, specifically the facet joints, which is commonly performed in spinal fusion procedures and Avance, an MIS pedicle screw system used in lumbar fusion procedures. Baxano Surgical was founded in May 2000 and is headquartered in Raleigh, North Carolina. For more information, visit www.baxanosurgical.com.

AxiaLIF, VEO, iO-Tome and iO-Flex are all registered trademarks of Baxano Surgical.

Forward Looking Statements
This press release includes statements that are based on our current beliefs and assumptions. These statements constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the pace of adoption of our product technology by spine surgeons, the outcome of coverage and reimbursement decisions by the government and third party payors, the success of our continuing product development efforts, the effect on our business of existing and new regulatory requirements, our ability to raise additional capital, our ability to comply with our settlement agreement and Corporate Integrity Agreement with certain entities of the U.S. government, stockholder class action lawsuits, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with Baxano Surgical’s business, please review the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2013 and subsequent reports. You are cautioned not to place undue reliance on these forward looking statements, which are based on Baxano Surgical’s expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward looking statement, whether as a result of new information, future events or otherwise.

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.



CONTACT:
Baxano Surgical Inc.
Tim Shannon, Chief Financial Officer
919-926-8762

or

Stonegate, Inc.
Casey Stegman
214-987-4121
casey@stonegateinc.com

Velocity Pharmaceutical Development

Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Regulatory Clearance for Initiating Phase II Study with VPD-737 in Prurigo Nodularis

South San Francisco, California – June 23, 2013

Velocity Pharmaceutical Development, LLC (“VPD”) and Tigercat Pharma, Inc., (“Tigercat”) announced today that they have met all regulatory requirements from Germany’s BfArM to initiate a Phase II clinical trial of VPD-737 (serlopitant) in patients with prurigo nodularis. Separately, VPD is also conducting a Phase II clinical trial in the United States evaluating VPD-737 in patients with chronic pruritus.

“Prurigo nodularis is a chronic, debilitating dermatological condition that frequently leads to permanent changes to the skin and prevents patients from living a normal and productive lifestyle. Unfortunately, current therapy options for this orphan disease remain poor thus the unmet medical need for a successful treatment alternative for prurigo nodularis and chronic pruritus remains high” said Prof. Dr. Sonja Ständer, the Principle Investigator for the study. Dr. Ständer is professor for Dermatology and Neurodermatology at the Department of Dermatology, and head of the Interdisciplinary Competence Center Chronic Pruritus of the University Hospital Münster, Germany.

“We are excited about Tigercat achieving another important milestone by starting this new clinical trial and look forward to share top-line results from this study and our chronic pruritus trial in early 2015”, said Dr. Edward Schnipper, Tigercat’s Chief Medical Officer.

The trial is a double-blind, placebo-controlled Phase II study in patients with prurigo nodularis, an orphan disease. The study is designed to determine the safety, tolerability, and efficacy of VPD-737, an NK-1 receptor antagonist, and will be conducted at four sites in Germany.

VPD-737 (serlopitant) was exclusively licensed to VPD from Merck in 2012.

About Tigercat Pharma, Inc.

Tigercat Pharma, Inc., is a largely “virtual” company which was created to hold

the ownership of the VPD-737 development program. Tigercat is funded by

Velocity Pharmaceutical Holdings, LLC, and Remeditex Ventures, LLC. The VPD-737

development program is managed under contract by VPD.

 

About Velocity Pharmaceutical Development, LLC

VPD is a pharmaceutical development organization dedicated to rapidly advancing

promising drug candidates to clinical proof of concept using a highly virtual

management model. VPD seeks to acquire promising drug candidates, generally

within a year of their entering human clinical trials or after initial human clinical

data have been generated. VPD then manages a development program for each drug

candidate intended to generate convincing human proof of concept data (generally

by conducting a phase 2 clinical trial). Following successful human proof of concept,

VPD then seeks a large pharmaceutical company acquirer for each program. VPD

is staffed by a seasoned team of clinical drug developers with expertise identifying

attractive drug candidates, target markets, and designing and managing outsourced

clinical trials. This expert team manages multiple single asset companies to remove

the costly overhead and misaligned incentives present in traditional biotechnology

company structures. VPD believes this new capital-efficient model will yield

attractive new drugs to treat patients with significant unmet clinical needs. The

company is located in South San Francisco, California. More information is available

at www.vpd.net.

 

About Velocity Pharmaceutical Holdings, LLC

Velocity Pharmaceutical Holdings, LLC, is an entity funded by CMEA Capital that

makes investments in highly virtual, project-focused pharmaceutical development

companies that are managed by Velocity Pharmaceutical Development, LLC. More

information is available at www.vpd.net and www.cmea.com.

 

About Remeditex Ventures, LLC

Remeditex is a company that seeks to develop opportunities in need of commercial

validation, guidance, and capital. Its mission is to develop early stage biomedical

science and make Texas and Colorado a preferred location for biotechnology

companies, venture capitalists, and entrepreneurs by accelerating the pace of

commercialization of biomedical research; help create and support a thriving

biotechnology industry; attract biotech venture capital to Texas and Colorado; and

achieve significant returns to support the next generation of promising science.

More information is available at www.remeditex.com.

 

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

 

Contact

Leslie Loven

1-415-524-7326

leslie@vpd.net

Ardelyx

Ardelyx Announces Pricing Of Its Initial Public Offering

FREMONT, Calif., June 18, 2014  — CMEA Capital portfolio company Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the pricing of its initial public offering of 4,286,000 shares of common stock at a public offering price of $14.00 per share. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol “ARDX” on June 19, 2014. In addition, Ardelyx has granted the underwriters a 30-day option to purchase up to an additional 642,900 shares of common stock at the initial public offering price to cover over-allotments, if any. The offering is expected to close on June 24, 2014 subject to customary closing conditions.

Citigroup and Leerink Partners are acting as joint book-running managers for the proposed offering. JMP Securities is acting as the lead manager and Wedbush PacGrow Life Sciences is acting as co-manager.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on June 18, 2014. The offering is being made only by means of a prospectus forming part of the effective registration statement. A copy of the final prospectus relating to these securities will be filed with the SEC and may be obtained, when available, from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, by email at batprospectusdept@citi.com or by phone at (800) 831-9146 or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at syndicate@leerink.com, or by phone at (800) 808-7525, ext. 4814.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Ardelyx, Inc.

Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, non-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The Company has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor, a product currently in Phase 2 clinical trials that has consistently demonstrated the ability to reduce the absorption of dietary sodium and phosphorus, both of which are recognized as key factors in the progression of kidney disease. Ardelyx formed a collaborative partnership with AstraZeneca in October 2012 to develop and commercialize tenapanor. In addition to tenapanor, the Company is evaluating small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in ESRD, a program licensed to Sanofi, and independently is advancing three additional research programs focused in cardio-renal, GI and metabolic diseases. Ardelyx is located in Fremont, California. For more information, please visit Ardelyx’s website at www.ardelyx.com.

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

 

 

Source: PRNewswire

Arcadia Biosciences

ARCADIA BIOSCIENCES LAUNCHES SONOVA® ULTRA GLA SAFFLOWER OIL

Next-Generation Dietary Supplement Offers the Highest Concentration of Oilseed GLA Available

DAVIS, Calif. (June 17, 2014) – CMEA Captial portfolio company Arcadia Biosciences, Inc., an agricultural biotechnology company focused on developing technologies and products that benefit the environment and enhance human health, announced the commercial launch of SONOVA® ULTRA GLA Safflower Oil. With 55 percent gamma linolenic acid (GLA), this addition to the company’s nutritional oils portfolio offers a GLA concentration more than twice as high as produced in any other commercial oilseed.

Traditional sources of GLA oil contain relatively low amounts of the important omega-6 fatty acid and are often difficult to cultivate, making supply erratic and expensive. Evening primrose oil contains approximately 10 percent GLA, and borage oil contains approximately 20 percent GLA. In 2011, Arcadia launched SONOVA® 400 GLA Safflower Oil, containing 40 percent GLA, to give consumers and formulators a more highly concentrated and cost-effective source of GLA. Consumers benefit by having to take fewer capsules per day to achieve a health benefit, and dietary supplement and medical food companies benefit through more efficient formulations.

Gamma linolenic acid is an important nutritional omega-6 fatty acid with documented health benefits that are similar and complementary to those of omega-3 fatty acids.

  • GLA provides dietary support for a wide range of conditions such as weight management, skin health and women’s health (hormonal balance), with the core of its health benefits related to its anti-inflammatory attributes.
  • GLA, in combination with the important omega-3 fatty acids EPA and DHA that are typically found in fish oil, has been shown to support heart and eye health and to reduce inflammation, asthma, diabetic neuropathy and rheumatoid arthritis.
  • Current GLA research is focused on childhood and adolescent ADHD/ADD, adult diabetes and metabolic syndrome, inflammation and cardiovascular disease, atopic dermatitis and acne.

“Consumers seeking to maximize the benefits of functional ingredients are demanding increased efficacy with smaller doses,” said Eric Rey, president and CEO of Arcadia. “SONOVA® ULTRA features the most highly concentrated commercial source of GLA produced in a seed oil today, offering dietary supplement companies greater flexibility in the development of nutritional and functional food products.”

When SONOVA® 400 GLA Safflower Oil was first introduced commercially in 2011, it represented a significant increase in GLA concentration over other dietary sources: four times the GLA concentration of evening primrose oil and twice the concentration of borage oil. SONOVA® ULTRA GLA Safflower Oil is the next generation product for applications requiring even higher levels of GLA.

Both SONOVA® 400 and SONOVA® ULTRA GLA Safflower Oil are grown and produced in the United States under strict Identity Preservation (IP) protocols. SONOVA® ULTRA GLA Safflower Oil is currently available in bulk oil and softgels. Arcadia also offers retail-ready packaged softgels.

Dietary supplement companies looking for a cost-efficient and sustainable source of highly concentrated GLA may find SONOVA® ULTRA GLA Safflower Oil to be their optimal solution.

For samples and more information, visit www.SonovaGLA.com.

###
About Arcadia Biosciences, Inc.
Based in Davis, Calif., with additional facilities in Seattle, Wash. and Phoenix, Ariz., Arcadia Biosciences is focused on the development of agricultural products that benefit the environment and enhance human health. Arcadia’s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salt Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition technologies and products create healthier ingredients and whole foods with lower production costs. The company was recently named one of MIT Technology Review’s 50 Smartest Companies

About CMEA Capital

CMEACapital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

Neos Therapeutics

Neos Therapeutics, Inc. Announces the Appointment of Richard I. Eisenstadt as Chief Financial Officer

Dallas/Fort Worth, TX  (May  22, 2014) – CMEA Capital portfolio company Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today the appointment of Richard I. Eisenstadt to the role of Chief Financial Officer, effective immediately.

 

Mr. Eisenstadt has over twenty-five years of finance leadership experience in the healthcare, life sciences and emerging technology industries.  Before joining Neos Therapeutics, he served as Chief Financial Officer of ArborGen Inc., a leader in the development and commercialization of technologies that improve the productivity of trees.  Prior to ArborGen, Mr. Eisenstadt was Vice President of Finance and Chief Financial Officer of Tranzyme Pharma (NASDAQ: TZYM), a drug discovery and development company, where he raised over $100 million in both private and public equity and debt financings, including an initial public offering of the company’s stock in April 2011.

 

Neos Therapeutics’ President and Chief Executive Officer, Vipin Garg, stated, “I am excited to welcome Rich to the Neos team. He brings an extensive track record of finance and business experience and a broad understanding of funding and managing growth companies. Rich will work closely with the organization and financial community to ensure funding of our existing pipeline, and expansion of the use of our proprietary controlled release technologies to create additional CR orally disintegrating tablets and CR liquids to bring to market.”

 

Prior to joining Tranzyme, Mr. Eisenstadt served as Director of Finance at Cogent Neuroscience, and held financial leadership positions at Nimbus CD International and Genicom Corporation.  Mr. Eisenstadt received his MBA from James Madison University and his BA in Economics from the University of North Carolina at Chapel Hill. He was the recipient of the Triangle Business Journal CFO of the Year award in 2011.

 

About Neos Therapeutics

 

Neos Therapeutics Inc., is a specialty pharmaceutical company focused on the development and manufacture of FDA approved drug products that utilize the Company’s proprietary and patented delivery technologies. The Neos drug products are being developed using the Dynamic Time  Release Suspension® (DTRS®) and Rapidly Disintegrating Ionic Masking™ (RDIM™) technologies that deliver controlled release (CR) small molecule active pharmaceutical ingredients (APIs) in either liquid or orally disintegrating tablet (ODT) dosage forms. By utilizing APIs that are already FDA-approved, Neos can reduce development and regulatory risk and efficiently advance targeted proprietary Rx products through the FDA’s New Drug Application (NDA) approval process. For more information, visit www.neostx.com.

 

This press release contains certain “forward-looking statements” that include projections and may also include words such as “may”, “will”, “expects”, “believes”, “anticipates”, “plans”, “estimates”, “seeks”, “could”, “intends”, and other similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.

 

 

CONTACT

Vipin K. Garg, Ph.D.

Chief Executive Officer

(919) 434-6643

vgarg@neostx.com

 

 

Richard I. Eisenstadt

Chief Financial Officer

(972) 408-1389

reisenstadt@neostx.com